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Abstract
Ebola virus (EBOV) is a significant human pathogen that presents a public health concern as an emerging/re-emerging virus
and as a potential biological weapon. Substantial progress has been made over the last decade in developing candidate
preventive vaccines that can protect nonhuman primates against EBOV. Among these prospects, a vaccine based on
recombinant vesicular stomatitis virus (VSV) is particularly robust, as it can also confer protection when administered as a
postexposure treatment. A concern that has been raised regarding the replication-competent VSV vectors that express EBOV
glycoproteins is how these vectors would be tolerated by individuals with altered or compromised immune systems such as
patients infected with HIV. This is especially important as all EBOV outbreaks to date have occurred in areas of Central and
Western Africa with high HIV incidence rates in the population. In order to address this concern, we evaluated the safety of
the recombinant VSV vector expressing the Zaire ebolavirus glycoprotein (VSVDG/ZEBOVGP) in six rhesus macaques infected
with simian-human immunodeficiency virus (SHIV). All six animals showed no evidence of illness associated with the VSVDG/
ZEBOVGP vaccine, suggesting that this vaccine may be safe in immunocompromised populations. While one goal of the
study was to evaluate the safety of the candidate vaccine platform, it was also of interest to determine if altered immune
status would affect vaccine efficacy. The vaccine protected 4 of 6 SHIV-infected macaques from death following ZEBOV
challenge. Evaluation of CD4+ T cells in all animals showed that the animals that succumbed to lethal ZEBOV challenge had
the lowest CD4+ counts, suggesting that CD4+ T cells may play a role in mediating protection against ZEBOV.
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Introduction
Ebola virus (EBOV) has been associated with sporadic episodes
of hemorrhagic fever (HF) that produce severe disease in infected
patients. Mortality rates in outbreaks have ranged from 50% for
Sudan ebolavirus (SEBOV) to up to 90% for Zaire ebolavirus (ZEBOV)
(reviewed in [1]). A recent outbreak caused by an apparently new
species of EBOV in Uganda appears to be less pathogenic than
SEBOV or ZEBOV with a preliminary case fatality rate of about
25% [2]. EBOV is also considered to have potential as a biological
weapon and is categorized as a Category A bioterrorism agent by
the Centers for Disease Control and Prevention [3–5].
While there are no vaccines or postexposure treatment
modalities available for preventing or managing EBOV infections
there are at least four different vaccine systems that have shown
promise in completely protecting nonhuman primates against a
lethal EBOV challenge [6–12]. Of these prospective EBOV
vaccines two systems, one based on a replication-defective
adenovirus and the other based on a replication-competent
vesicular stomatitis virus (VSV), were shown to provide complete
PLoS Pathogens | www.plospathogens.org 1 November 2008 | Volume 4 | Issue 11 | e1000225protection when administered as a single injection vaccine [7–9].
Most intriguingly, the VSV-based vaccine is the only vaccine
which has shown any utility when administered as a postexposure
treatment [13,14].
Of these two leading EBOV vaccine candidates that can confer
protection as single injection vaccines each has advantages and
disadvantages. Adenovirus vectors are highly immunogenic as
documented by clinical trials evaluating gene transfer efficacy and
immune responses. Because they are replication-defective adeno-
virus vectors are also perceived to be safer for human use than a
replication-competent vaccine. The most significant challenge for
the adenovirus-based vaccines is the concern that a significant
portion of the global population has pre-existing antibodies against
the adenovirus vector which may affect efficacy [15–17] and has
performed poorly as a vaccine vector in recent clinical trials [18–
19]. In contrast, pre-existing immunity against VSV in human
populations is negligible [20] and efficacy is likely greater with
replication-competent vectors. The main concern with the VSV
vaccine vector is that replication-competent vectors may present
more significant safety challenges in humans particularly those
with altered immune status.
Because EBOV outbreaks in man have occurred exclusively in
Central and Western Africa, the populations in this region are
among those that may benefit from the development and
availability of an EBOV vaccine. However, populations in this
region are among the most medically disadvantaged in the world.
In particular, the prevalence of individuals with a compromised
immune system is high and HIV infections rates range up to 10%
or more in this area [21]. While the VSV vaccine vector has been
enormously successful in protecting healthy immunocompetent
animals against EBOV [7,13,14], we are uncertain as to how these
vectors would behave in individuals with altered or compromised
immune systems. Therefore, we conducted a study to assess the
pathogenicity and protective efficacy of the recombinant VSV-
based ZEBOV vaccine vector in rhesus macaques that were
infected with simian-human immunodeficiency virus (SHIV)
which is known to deplete the populations of naive CD4+ T cells,
naive CD8+ T cells, and memory CD4+ T cells in these animals
[22,23]. In order to take into account the degree or severity of
compromised immune function animals were selected with varying
degrees of CD4+ T cell loss.
Methods
Vaccine Vectors and Challenge Virus
The recombinant VSV expressing the glycoprotein (GP) of
ZEBOV (strain Mayinga) (VSVDG/ZEBOVGP) was generated as
described recently using the infectious clone for the VSV, Indiana
serotype [24]. ZEBOV (strain Kikwit) was isolated from a patient
of the ZEBOV outbreak in Kikwit in 1995 [25].
Animal Studies
Nine filovirus-seronegative adult rhesus macaques (Macaca
mulatta) (5–10 kg) were used for these studies. The macaques were
infected three months prior to the current study with SHIV162p3
(kindly provided by Dr. Ranajit Pal, Advanced BioScience
Laboratories, Inc., Kensington, MD). These animals all had
clinical laboratory evidence of SHIV infection as evidenced by
reduced CD4+ T cell counts, decreased ratios of CD4+/CD8+ T
cells (Table 1) and the presence of SHIV in plasma of four out of
nine animals (Table 2). Six of the nine SHIV-infected animals
were vaccinated by i.m. injection with ,1610^7 recombinant
VSVDG/ZEBOVGP. Three animals served as placebo controls
and were injected in parallel with saline. All six VSVDG/
ZEBOVGP-vaccinated animals and two of the three control
Author Summary
Ebola virus is among the most lethal microbes known to
man, with case fatality rates often exceeding 80%. Since its
discovery in 1976, outbreaks have been sporadic and
geographically restricted, primarily to areas of Central
Africa. However, concern about the natural or unnatural
introduction of Ebola outside of the endemic areas has
dramatically increased both research interest and public
awareness. A number of candidate vaccines have been
developed to combat Ebola virus, and these vaccines have
shown varying degrees of success in nonhuman primate
models. Safety is a significant concern for any vaccine and
in particular for vaccines that replicate in the host. Here,
we evaluated the safety of our replication-competent
vesicular stomatitus virus (VSV)-based Ebola vaccine in
SHIV-infected rhesus monkeys. We found that the vaccine
caused no evidence of overt illness in any of these
immunocompromised animals. We also demonstrated that
this vaccine partially protected the SHIV-infected monkeys
against a lethal Ebola challenge and that there appears to
be an association with levels of CD4+ lymphocytes and
survival. Our study suggests that the VSV-based Ebola
vaccine will be safe in immunocompromised populations
and supports further study and development of this
promising vaccine platform for its use in humans.
Table 1. Pre-vaccination hematology of SHIV-infected rhesus macaques.
Animal No. Pre-SHIV CD4 Post-SHIV CD4 CD4 % Drop Pre-SHIV CD4/CD8 Post-SHIV CD4/CD8 CD4/CD8 %Change
Subject 1 2610 541 79 1.17 0.45 61
Subject 2 1207 627 48 1.03 0.44 57
Subject 3 861 595 31 0.68 0.48 29
Subject 4 1380 681 51 0.64 0.26 59
Subject 5 509 83 84 0.86 0.09 89
Subject 6 1193 42 96 0.92 0.03 97
Control 1 846 329 61 1.16 0.16 86
Control 2 731 289 60 1.00 0.29 71
Control 3 651 288 56 0.59 0.25 58
doi:10.1371/journal.ppat.1000225.t001
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tion with 1000 pfu of ZEBOV (strain Kikwit). The monkeys were
challenged with the heterologous Kikwit strain of ZEBOV as our
macaque models have been developed and characterized using
this strain [1,26]. Animals were closely monitored for evidence of
clinical illness (e.g., temperature, weight loss, changes in complete
blood count, and blood chemistry) during both the vaccination
and ZEBOV challenge portions of the study. In addition,
VSVDG/ZEBOV and ZEBOV viremia and shedding were
analyzed after vaccination and challenge, respectively. Animals
were given physical exams and blood and swabs (nasal, oral, rectal)
were collected at 2, 4, 7, 10, 14, 21, 28, and 31 days after
vaccination and on days 3, 6, 10, 15, and 28 after ZEBOV
challenge. The vaccination portion of the study was conducted at
BIOQUAL and was approved by NIAID, BIOQUAL, and
USAMRIID Laboratory Animal Care and Use Committees. The
ZEBOV challenge was performed in BSL-4 biocontainment at
USAMRIID and was approved by the USAMRIID Laboratory
Animal Use Committee. Animal research was conducted in
compliance with the Animal Welfare Act and other Federal statues
and regulations relating to animals and experiments involving
animals and adheres to the principles stated in the Guide for the Care
and Use of Laboratory Animals, National Research Council, 1996.
Both facilities used are fully accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care
International.
Hematology and Serum Biochemistry
Total white blood cell counts, white blood cell differentials, red
blood cell counts, platelet counts, hematocrit values, total
hemoglobin, mean cell volume, mean corpuscular volume, and
mean corpuscular hemoglobin concentration were determined
from blood samples collected in tubes containing EDTA, by using
a laser-based hematologic Analyzer (Coulter Electronics, Hialeah,
FL, USA). The white blood cell differentials were performed
manually on Wright-stained blood smears. Serum samples were
tested for concentrations of albumin (ALB), amylase (AMY),
alanine aminotransferase (ALT), aspartate aminotransferase
(AST), alkaline phosphatase (ALP), gamma-glutamyltransferase
(GGT), glucose (GLU), cholesterol (CHOL), total protein (TP),
total bilirubin (TBIL), blood urea nitrogen (BUN), and creatinine
(CRE) by using a Piccolo Point-Of-Care Blood Analyzer (Abaxis,
Sunnyvale, CA, USA).
Flow Cytometry for Circulating Cell Populations
100 ul of whole blood was added to a 12675 tube and incubate
with the antibodies for 15 minutes at room temperature. The
samples was then lysed and fixed in 1% paraformaldehyde and
washed three times in PBS. Samples were analyzed on a Becton
Dickinson FACS Calibur (Becton Dickinson, San Jose, CA). All
antibodies were purchased from Becton Dickinson; clones used were
CD3 – SP34, CD4 – L200, CD8 – RPA-T8 and CD20 – 2H7.
Detection of SHIV
For measurement of plasma SIV RNA levels, a quantitative
TaqMan RNA reverse transcription-PCR (RT-PCR) assay (Applied
Biosystems, Foster City, CA) was used, which targets a conserved
region of SIV gag and has an accurate detection limit as low as 200
RNA copies/ml. Briefly, isolated plasma viral RNA was used to
generate cDNA using One-Step RT-PCR Master Mix (Applied
Biosystems). The samples were then amplified as previously
described [27] with the following PCR primer/probes: SIV-F 59
AGTATGGGCAGCAAATGAAT 39 (forward primer), SIV-R
59TTC TCTTCTGCGTG AATGC 39 (reverse primer), SIV-P
6FAM-AGATTTGGATTAGCAGAAAGCCTGTTG GA-
TAMRA (TaqMan probe) in a 7700 Sequence Detection System
(40 cycles of 95uC, 15 seconds, and 60uC, 1 minute). The signal was
then compared to a standard curve of known concentrations to
determine the viral copies present in each sample. The assay lower
limit was 40 copies/ml.
Detection of VSV and ZEBOV
RNA was isolated from blood and swabs using Tripure Reagent
(INVITROGEN, Grand Island, New York). For the detection of
VSV we used a Q-RT-PCR assay targeting the matrix gene (nt
position 2497–2556, AM690337). ZEBOV RNA was detected
using a Q-RT-PCR assay targeting the L gene (nt position 13874–
13933, AY354458). The low detection limit for this ZEBOV assay
is 0.1 pfu/ml of plasma. Virus titration was performed by plaque
assay on Vero E6 cells from all blood and selected organ (liver,
spleen, lung, kidney, adrenal gland, pancreas, axillary lymph node,
inguinal lymph node, mesenteric lymph node, ovary or testis, and
brain) and swab samples. Briefly, increasing 10-fold dilutions of the
samples were adsorbed to Vero E6 monolayers in duplicate wells
(0.2 ml per well); thus, the limit for detection was 25 pfu/ml.
Humoral Immune Response
IgG antibodies against ZEBOV were detected with an Enzyme-
Linked Immunosorbent Assay (ELISA) using purified virus
particles as an antigen source as previously described [7,9].
Histology and Immuohistochemistry
Necropsies were performed on each animal and selected tissues
were collected for histological analysis. Histology and immuno-
histochemistry were performed as previously described for
ZEBOV-infected monkeys [26].
Results
We employed nine SHIV-infected rhesus macaques, of which
six animals were vaccinated by i.m. injection with a single dose of
VSVDG/ZEBOVGP (Subjects #1–6) and the remaining three
animals (Controls #1–3) received sterile saline. The animals were
monitored closely for clinical symptoms and shedding of
recombinant VSVs. None of the animals vaccinated with
VSVDG/ZEBOVGP or treated with saline showed overt fever
or any evidence of clinical illness during the 31 day vaccination
period. Importantly, no evidence of reaction at the vaccine
Table 2. SHIV load determined by a nucleic acid sequence-
based amplification assay.
Animal No. Day 0* Day 2 Day 7 Day 10 Day 28
Subject 1 ,40 ,40 ,40 ,40 ,40
Subject 2 ,40 ,40 ,40 ,40 ,40
Subject 3 ,40 ,40 400 1920 ,40
Subject 4 ,40 ,40 ,40 ,40 ,40
Subject 5 3420 7760 9700 8720 22480
Subject 6 22760 9900 11800 21880 8380
Control 1 900 400 960 1780 ,40
Control 2 ,40 ,40 ,40 ,40 ,40
Control 3 ,40 ,40 ,40 ,40 ,40
*Days after vaccination; values listed as genomes/ml of blood.
doi:10.1371/journal.ppat.1000225.t002
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vaccinated animals nor was any change noted in activity or
behavior during the vaccination phase of the study (day 0 to day 31
after vaccination). In addition, no changes were detected in
hematology or clinical chemistry following vaccination. A mild
VSVDG/ZEBOVGP viremia (,10
3 pfu/ml) was detected only on
day 2 after vaccination by virus isolation (Figure 1) and RT-PCR
(data not shown) in four of the six VSVDG/ZEBOVGP-immunized
macaques (Subjects #1, 2, 3, 4). Surprisingly, the two animals with
the lowest CD4+ counts (subjects #5, 6) never showed any
detectable level of VSV viremia. VSVDG/ZEBOVGP was
undetectable in all analyzed swab samples (data not shown). Thus,
vaccination led to a transient viremia from virus replication at as yet
undetermined sites but no virus shedding of the vaccine virus.
Following successful completion of the safety portion of the
study all six of the VSVDG/ZEBOVGP-vaccinated SHIV-
infected monkeys and two of the three placebo control SHIV-
infected monkeys were challenged 31 days after the single
immunization by i.m. injection with 1000 pfu of ZEBOV (strain
Kikwit). Four of the six VSVDG/ZEBOVGP-vaccinated SHIV-
infected monkeys and both of the placebo control animals started
to show clinical signs of disease on day 6 after challenge including
fever (Subject # 1, 2 and Control #1, 2) and lymphopenia and
thrombocytopenia (Subject #2, 5, 6 and Control #1, 2) (Table 3).
Disease progressed in two of the VSVDG/ZEBOVGP-vaccinated
SHIV-infected monkeys (Subject #5 and 6) and both of the
placebo control animals with the development of additional
evidence of clinical illness including increased levels of serum
enzymes associated with liver function,depression,anorexia,and the
appearance of macular rashes (Table 3). All four of these animals
succumbed to the ZEBOV challenge with the two VSVDG/
ZEBOVGP-vaccinated monkeys expiring on days 9 (Subject #6)
and 13 (Subject #5) and the placebo controls succumbing on days 9
(Control#1)and10(Control#2)afterZEBOVchallenge(Figure2).
DiseasedidnotprogressinthetwoVSVDG/ZEBOVGP-vaccinated
SHIV-infected monkeys that were febrile (Subjects #1, 2) and had
changes in hematology values on day 6 (Subjects #2) and both of
these animals remained healthy and survived the ZEBOV challenge
(Figure 2). The remaining VSVDG/ZEBOVGP-vaccinated ma-
caques (Subject #3, 4) never showed any evidence of clinical illness
and survived (Figure 2). Interestingly, the VSVDG/ZEBOVGP-
vaccinated macaques that succumbed were the two animals with the
mostsignificantreduction inCD4+ T cells (84%, 96%)(Table 1), the
lowest total CD4+ T cell counts (83, 42) (Table 1), the highest SHIV
viremia (Table 2), and no evidence for VSV viremia (Figure 1)
suggesting that CD4+ T cells may play a role in protection.
Blood samples were analyzed after challenge for evidence of
ZEBOV replicationbyplaqueassayand RT-PCR.By day6,bothof
the placebo control animals developed high ZEBOV titers in plasma
as detected by plaque assay (.10
4.5 log pfu/ml) (Table 4). In
comparison, only one of the VSVDG/ZEBOVGP-vaccinated
monkeys (Subject #6) showed a ZEBOV viremia at day 6 by
plaque assay (,10
2 log pfu/ml) (Table 4). ZEBOV was detected in a
second VSVDG/ZEBOVGP-vaccinated monkey (Subject #5) by
day 10 (,10
4.2 log pfu/ml). RT-PCR was more sensitive and
showed evidence of ZEBOV inplasma of this animal(Subject#5) at
day6.Inaddition,RT-PCRwasmoresensitiveindetectingZEBOV
in swabs which were positive on a number of samples derived from
Subject #5 at day 6 and day 10 (Table 4). In contrast, no ZEBOV
was detected in the plasma by virus isolation or RT-PCR in the four
VSVDG/ZEBOVGP-vaccinated monkeys that survived ZEBOV
challenge. Moreover, no evidence for reactivation of VSVDG/
ZEBOVGP was detected from any blood or swab sample from any
animal after ZEBOV challenge (data not shown). Although we failed
to detect ZEBOV viremia in the two surviving animals that were
clinically ill (Subject#1 and 2) at days 3, 6, 10, and 14 after ZEBOV
challenge we cannot exclude the possibility that these animals had
low levels of circulating ZEBOV at time points not evaluated.
The four surviving VSVDG/ZEBOVGP-vaccinated macaques
(Subjects #1, 2, 3, 4) were euthanized 28 days after the ZEBOV
challenge to perform a virological and pathological examination of
tissues. Organ infectivity titration from these four animals showed
no evidence of ZEBOV in any of the tissues examined. In
comparison, ZEBOV was recovered from tissues of both
VSVDG/ZEBOVGP-vaccinated animals that succumbed (Subject
#5, 6) and both SHIV-infected control animals. Organ titers of
infectious ZEBOV were consistent with values previously reported
for immunocompetent ZEBOV-infected rhesus macaques [27,28].
VSVDG/ZEBOVGP was not recovered in any of the tissues
examined from any animal on this study.
Figure 1. Plasma levels of VSVDG/ZEBOVGP from rhesus macaques after vaccination.
doi:10.1371/journal.ppat.1000225.g001
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from the four VSVDG/ZEBOVGP-vaccinated animals (Subjects
#1, 2, 3, 4) that survived ZEBOV challenge showed no evidence
of ZEBOV antigen. In contrast, ZEBOV antigen was readily
detected in typical target organs (e.g., liver, spleen, adrenal gland,
lymph nodes) of the two VSVDG/ZEBOVGP-vaccinated animals
that succumbed to ZEBOV challenge (Subject #5, 6) (Figure 3)
and the two placebo controls. Lesions and distribution of ZEBOV
antigen in these macaques was consistent with results reported in
other studies [27,29].
While cellular immune responses against ZEBOV GP in
macaques vaccinated with VSVDG/ZEBOVGP vectors have
been difficult to detect before challenge in previous studies [7],
humoral immune responses have been more robust and consistent
([7]; TW Geisbert, unpublished observations). Therefore, we
measured the antibody responses of the rhesus macaques
vaccinated with VSVDG/ZEBOVGP before vaccination (day
27), after vaccination (day 14 and day 31), and after ZEBOV
challenge (day 46 and day 59 after vaccination) by IgG ELISA.
None of the six VSVDG/ZEBOVGP-vaccinated macaques
developed IgG antibody titers against the ZEBOV GP by the
day of ZEBOV challenge (Figure 4). Two animals (Subjects #1, 2)
developed modest IgG antibody titers against ZEBOV by day 15
after ZEBOV challenge (day 46 after vaccination) while a third
animal developed a titer by day 28 after ZEBOV challenge (day 59
after vaccination) (Figure 4).
Discussion
An often raised concern regarding the use of the recombinant
VSV vaccine platform in humans is related to the fact that this is a
replication-competent vaccine, and thus demonstration of safety is
of paramount importance. Taking into account our previous work
it is not surprising that the VSVDG/ZEBOVGP was tolerated
well in our SHIV-infected macaques. Specifically, we failed to
observe evidence of any adverse events in a large cohort of over 90
macaques receiving VSV vectors expressing different GPs from
viral HF agents (38 cynomolgus macaques and 3 rhesus macaques
vaccinated with VSVDG/ZEBOVGP; 12 cynomolgus macaques
Table 3. Clinical findings in SHIV-infected rhesus monkeys challenged with ZEBOV.
Animal Day 0–8 Day 9–10 Day 11–28
Day of
Death
Subject 1 Fever (6) Survived





Subject 5 Lymphopenia (6), Thrombocytopenia (6) Anorexia (10), Depression (10), ALTq (10),
ASTqqq (10), BUNq (10), GGTq (10)
Anorexia (11–13), Depression (11–13),
Moderate rash (12–13), ALBQ (13),
ALPqq (13), ALTqqq (13), ASTqqq
(13), AMYQ (13), BUNqqq (13), CREq
(13), GGTqqq (13), UAq (13), GLUQ (13)
Day 13
Subject 6 Anorexia (7–8), Depression (7–8), Mild rash
(8), Lymphopenia (6), Thrombocytopenia (6)
Day 9
Control 1 Fever (6), Anorexia (7–8), Depression (8),
Mild rash (6–8), Lymphopenia (6),
Thrombocytopenia, ALPq (6), ASTqqq
(6)
Anorexia (9), Depression (9), Moderate
rash (9), Epistaxis (9), Thrombocytopenia
(9), ALPqqq (9), ALTqqq (9),
ASTqqq (9), BUNqqq (9), CREqqq
(9), GGTqqq (9), GLUQ (9)
Day 9
Control 2 Fever (6), Anorexia (8), Depression (8),
Lymphopenia (6), Thrombocytopenia (6),
ALPqq (6), ASTq (6)
Anorexia (9), Depression (9), Moderate
rash (9)
Day 10
Fever is defined as a temperature more than 2.5 uF over baseline or at least 1.5 uF over baseline and $103.5 uF.
Mild rash: focal areas of petechiae covering less than 10% of the skin; moderate rash: areas of petechiae covering between 10% and 40% of the skin; severe rash: areas of
petechiae and/or echymosis covering more than 40% of the skin.
Lymphopenia and thrombocytopenia defined by $35% drop in numbers of lymphocytes and platelets, respectively.
Alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase (GGT), blood urea nitrogen (BUN), creatinine
(CRE), uric acid (UA), Albumin (ALB), Amylase (AMY), Glucose (GLU).
q=2–3 fold increase; qq=4–5 fold increase; qqq=.5 fold increase; Q=2–3 fold decrease.
( ) Days after ZEBOV challenge are shown in parentheses.
doi:10.1371/journal.ppat.1000225.t003
Figure 2. Kaplan-Meier survival curves for SHIV-infected
rhesus macaques vaccinated with VSVDG/ZEBOVGP and
challenged 31 days later with ZEBOV.
doi:10.1371/journal.ppat.1000225.g002
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GP; 29 cynomolgus macaques and 3 rhesus macaques vaccinated
with VSV expressing the Marburg virus GP; and 6 cynomolgus
macaques vaccinated with VSV expressing the Lassa GP)
([7,30,31]; TW Geisbert, H Feldmann, and SM Jones unpublished
observations). We have also failed to observe any adverse events in
a variety of immunocompetent laboratory mice (different inbred
strains), outbred guinea pigs (Hartley strain) and goats vaccinated
with the above mentioned VSV vectors at doses ranging from
2610
0–2610
5 pfu ([24,32]; SM Jones and H Feldmann, unpub-
lished observations). More recently we have also demonstrated
that vaccination of severely immunocompromised SCID mice with
Table 4. Viral load in SHIV-infected rhesus monkeys after ZEBOV challenge.
Animal No. Plasma PBMC Throat Nasal Rectal Vaginal
D6 D1 0 D6 D1 0 D6 D1 0 D6 D1 0 D6 D1 0 D6 D1 0
Subject 1 0* 0 NT NT 0 0 0 0 NT NT NT NT
(2)( 2)( 2)( 2)( 2)( 2)( 2)( 2)( 2)( 2)( 2)( 2)
Subject 2 0 0 NT NT 0 0 0 0 NT NT NT NT
(2)( 2)( 2)( 2)( 2)( 2)( 2)( 2)( 2)( 2)( 2)( 2)
Subject 3 0 0 NT NT 0 0 0 0 NT NT NA NA
(2)( 2)( 2)( 2)( 2)( 2)( 2)( 2)( 2)( 2)N A N A
Subject 4 0 0 NT NT 0 0 0 0 NT NT NA NA
(2)( 2)( 2)( 2)( 2)( 2)( 2)( 2)( 2)( 2)N A N A
Subject 5 0 4.2 NT NT 0 2.2 0 0 NT NT NT NT
(+)( +)( +)( 2)( 2)( +)( 2)( +)( 2)( +)( 2)( +)
Subject 6 2.0 NT 0 0 NT NT
(+)( +)( 2)( 2)( 2)( 2)
Control 1 5.4 NT 0 0 NT NT
(+)( +)
Control 2 4.9 NT 0 0 NT NT
(+)( +)( 2)( 2)( 2)( 2)
*, Log 10 pfu of ZEBOV per ml of plasma; (+), sample positive for ZEBOV by RT-PCR; (2), sample negative for ZEBOV by RT-PCR; NT, not tested; NA, not applicable.
doi:10.1371/journal.ppat.1000225.t004
Figure 3. Tissues from SHIV-infected rhesus monkeys vaccinated with VSVDG/ZEBOVGP and challenged 31 days later with ZEBOV.
(Left panel) Immunohistochemical staining of liver from animal that succumbed on day 9 (Subject 6) for ZEBOV. Note abundance of EBOV antigen
(brown) associated with sinusoids. (Right panel) Immunohistochemical staining of lymph node from animal that succumbed on day 13 (Subject 5) for
ZEBOV. Note localization of ZEBOV antigen (brown) associated with macrophages and dendritiform cells. Original magnifications, 620.
doi:10.1371/journal.ppat.1000225.g003
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5 pfu of the VSV-based ZEBOV vaccine (VSVDG/
ZEBOVGP) resulted in no clinical symptoms [32]. While transient
VSV viremia in this study was only observed in surviving
macaques but not in animals that had succumbed to ZEBOV
challenge (Figure 1), viremia data from previous studies [7,30,31]
do not support any correlation between VSV viremia and survival.
In addition, no evidence for vaccine vector shedding was detected
in this study supporting previous results [7,30,31] with no
compelling evidence to suggest that occasional virus shedding
(only detected by RT-PCR; negative on virus isolation) would lead
to vaccine vector transmission.
The VSV glycoprotein exchange vector that we employed in
this study has also shown promise as a preventive vaccine and
postexposure treatment against Marburg HF [30,33] and as a
preventive vaccine against Lassa fever in nonhuman primates [31].
Similar recombinant VSV vectors have been evaluated in animal
models as vaccine candidates for a number of viruses that cause
disease in humans including HIV-1, influenza virus, respiratory
syncytial virus, measles virus, herpes simplex virus type 2, hepatitis
C virus, and severe acute respiratory syndrome coronavirus [34–
40]. Many of these studies have employed VSV vectors that
maintained either the entire VSV glycoprotein (G) or the
transmembrane and/or cytoplamic domains of this protein to
facilitate more efficient incorporation of the foreign antigen. It is
known that VSV G is an important VSV protein associated with
pathogenicity [38,41]. It has been shown that truncation of the
cytoplasmic tail has greatly reduced vector pathogenicity in mice
following intranasal inoculation indicating the importance of this
domain for pathogenicity [42]. In this regard, a VSV vector
including portions of the VSV G and expressing HIV genes was
found to be insufficiently attenuated for clinical evaluation when
assessed for neurovirulence in nonhuman primates [43]. These
investigators subsequently showed that safety and immunogenicity
can be improved by genetic manipulation of the VSV genome but
it remained unclear whether neurovirulence was associated with
the VSV G or other genome manipulations [44]. Nevertheless, our
ZEBOV vaccine is a G-deficient VSV vector [24] and thus lacks
G-associated pathogenicity [41] as well as the target for VSV-
specific neutralizing antibodies [45]. Aside from G, the VSV
matrix (M) protein has been associated with cytopathic effects in
vitro including the inhibition of host gene expression, induction of
cell rounding and induction of apoptosis [46,47]. It is largely
unclear to what extent M alone contributes to pathogenicity, but
inoculation studies with the VSV-based vaccines in different
animal species (as described above) do not suggest a major
pathogenic effect of the M protein in vivo [7,13,32].
Currently, the mechanism by which any filovirus vaccine
confers protection in nonhuman primates is not well understood.
Nearly all studies have detected modest to good humoral immune
responses. For the VSVDG/ZEBOVGP vaccine a humoral
response is detected in macaques by day 14 after vaccination
([7]; TW Geisbert, unpublished observations). However, in the
current study and consistent with an impaired immune system, our
SHIV-infected macaques did not develop a humoral immune
response by the time of ZEBOV challenge. Three animals
developed modest anti-ZEBOV IgG titers 14 to 28 days after
ZEBOV challenge. We are uncertain as to why four of the six
VSVDG/ZEBOVGP-vaccinated macaques survived ZEBOV
challenge. Regardless of any humoral immune response elicited
in these animals it is unlikely that antibody alone confers
protection. Specifically, passive antibody studies in nonhuman
primates using a variety of anti-ZEBOV immune reagents
including polyclonal equine immune globulin [25], a recombinant
human monoclonal antibody [48], and convalescent monkey
blood [49] have uniformly failed to provide protection and more
importantly have failed to provide any beneficial effect.
A number of studies have evaluated the cellular immune
response in nonhuman primates vaccinated against EBOV and the
results have been mixed with some studies showing a modest
cellular response and other studies showing weak and/or no
Figure 4. Circulating levels of IgG against ZEBOV from SHIV-infected rhesus macaques vaccinated with VSVDG/ZEBOVGP and
challenged 31 days later with ZEBOV.
doi:10.1371/journal.ppat.1000225.g004
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intracellular cytokine assays that have been employed in some of
these studies are not sensitive or thorough enough to detect a
cellular immune response against ZEBOV. Indeed, it has been
reported that the inability to demonstrate a robust cellular
response may illustrate the limitation of the evaluation of cellular
immune responses using small numbers of functional measure-
ments (such as interferon-gamma) [50]. One interesting finding in
the current study may begin to shed some light on the mechanism
of protection elicited by the VSVDG/ZEBOVGP. Notably, the
two rhesus macaques that grouped together with the most severe
loss of CD4+ T cells were the only animals that failed to survive
ZEBOV challenge. This suggests that CD4+ T cells may play a
role in mediating protective immunity in EBOV infections. CD4+
T cells have been shown to be depleted in nonhuman primate
following ZEBOV infections [27,51] and in vitro ZEBOV infection
of human peripheral blood mononuclear cells causes massive
bystander death of CD4+ T cells by apoptosis [52]. While rodents
do not appear to faithfully reproduce ZEBOV infection of humans
and nonhuman primates [53] studies have suggested that CD4+ T
cells are required for protection of rodents against ZEBOV.
Specifically, in a study using liposome-encapsulated ZEBOV
antigens, Rao and colleagues showed that treatment of mice with
anti-CD4 antibodies before or during vaccination abolished
protection, while treatment with anti-CD8 antibodies had no
effect, thus indicating a requirement for CD4+ T lymphocytes for
successful immunization [54]. Similarly, depletion of CD8+ T cells
did not compromise protection in mice indicating that CD8+
cytotoxic T cells are not a requirement for protection [32].
In conclusion, our results show that the VSV-based ZEBOV
vaccine (VSVDG/ZEBOVGP) did not cause any illness in
immunocompromised SHIV-infected rhesus macaques and result-
ed in sufficient protective efficacy in all but the most severely
compromised animals against a lethal ZEBOV challenge.
Protection in the immunocompromised macaques appeared to
be dependent on CD4+ T cells rather than the development of
EBOV-specific antibodies. This provides strong support for the
safety of the VSV-based vectors and further development of this
promising vaccine platform for its use in humans. While these data
are very encouraging, as the number of SHIV-infected macaques
in the current study was small, additional safety studies will be
needed in order to determine whether vaccines based on
attenuated VSV will ultimately prove safe in immunocompro-
mised humans.
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